Arcturus Therapeutics is developing a portfolio of mRNA therapeutics for treatment of diseases with unmet medical needs. Our hope and vision are to build transformative, life-changing medicines for patients and their families.
Our team has extensive experience in the discovery and development of mRNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely position us to catalyze the next generation of mRNA medicines.
August 4, 2020
Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020
July 31, 2020
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 29, 2020
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock